|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02633 JACOBSON PHARMA
Nominal 
0.800 0.000 (0.000%) Profitability Analysis
| 2024/03 | 2023/03 | 2022/03 | 2021/03 | 2020/03 | |
| ROAA (%) | 6.021% | 4.953% | 3.693% | 3.677% | 4.878% |
| ROAE (%) | 10.451% | 9.604% | 7.280% | 7.051% | 8.318% |
| Return on Capital Employed (%) | 8.573% | 5.314% | 4.522% | 4.350% | 5.597% |
Margin Analysis
| 2024/03 | 2023/03 | 2022/03 | 2021/03 | 2020/03 | |
| Gross Profit Margin (%) | 42.273% | 41.845% | 38.891% | 38.805% | 43.907% |
| EBITDA Margin (%) | 30.722% | 32.319% | 28.304% | 30.835% | 30.466% |
| Pre-tax Profit Margin (%) | 17.345% | 19.028% | 14.505% | 15.255% | 16.767% |
| Net Profit Margin (%) | 18.188% | 14.060% | 11.135% | 12.014% | 13.722% |
Liquidity Analysis
| 2024/03 | 2023/03 | 2022/03 | 2021/03 | 2020/03 | |
| Current Ratio (X) | 2.587 X | 2.677 X | 1.426 X | 1.328 X | 1.609 X |
| Quick Ratio (X) | 1.734 X | 2.117 X | 1.045 X | 0.921 X | 1.098 X |
Leverage Analysis
| 2024/03 | 2023/03 | 2022/03 | 2021/03 | 2020/03 | |
| Total Liabilities / Total Assets(%) | 31.274% | 39.475% | 37.800% | 41.236% | 43.101% |
| Total Debt / Total Assets (%) | 21.492% | 29.720% | 29.648% | 33.872% | 35.984% |
| Net Debt / Total Assets (%) | 9.678% | 10.457% | 19.583% | 24.003% | 26.858% |
| Total Debt / Shareholders' Funds (%) | 31.591% | 58.431% | 56.594% | 68.984% | 64.945% |
| Long Term Debt / Shareholders' Funds (%) | 25.703% | 45.847% | 30.658% | 38.780% | 41.849% |
| Net Debt / Shareholders' Funds (%) | 14.225% | 20.559% | 37.381% | 48.885% | 48.474% |
| Net Cash / (Debt) ($) | (337.442M) | (562.646M) | (931.286M) | (1.168B) | (1.230B) |
| Net Cash / (Debt) per share ($) | (0.169) | (0.291) | (0.481) | (0.604) | (0.615) |
| Total Debt / Capital Employed (%) | 24.065% | 33.849% | 35.884% | 41.285% | 42.777% |
| Interest Coverage Ratio (X) | 4.235 X | 6.038 X | 10.010 X | 8.317 X | 5.760 X |
Efficiency Analysis
| 2024/03 | 2023/03 | 2022/03 | 2021/03 | 2020/03 | |
| Inventory Turnover (Day) | 147.723 Day | 119.960 Day | 125.546 Day | 150.079 Day | 146.021 Day |
| Receivables Turnover (Day) | 57.327 Day | 61.036 Day | 65.190 Day | 58.174 Day | 48.091 Day |
| Payables Turnover (Day) | 16.404 Day | 13.359 Day | 10.186 Day | 9.417 Day | 8.881 Day |
| Remarks: | Real time quote last updated: 27/11/2024 09:37 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders ($) | HKD 140,290,000 |
| %Change | -8.926% |
| EPS / (LPS) | HKD 0.071 |
| NBV Per Share ($) | HKD 1.216 |